Samantha Peacock is an associate in the London office of Latham & Watkins and a member of the firm’s Corporate Department.

Samantha advises on a broad range of corporate matters, including mergers and acquisitions, private equity, and venture capital investments. Samantha has particular expertise and interest in the life sciences sector.

Samantha trained in-house at pharmaceutical company Actavis (now part of the Teva group) where she gained a broad range of corporate and commercial experience. Her training included a six-month secondment to Latham's Corporate Department.

Samantha's experience includes advising:

Venture Capital - Investor Side

  • Octopus Ventures on its investments into Vira Health, Automata, and Touchlab spanning from pre-seed to Series B
  • Hoxton Ventures on its lead investments in Skin Analytics, Bother, Slice, and Luminary ROLI
  • VEON Ventures on its strategic investments in the Series A and B rounds of into Bangladesh based ShopUp in and Series A round of Pakistan based Dastgyr
  • Novo on its Series D investment in Quanta Dialysis
  • Citi Ventures on its investment in GoHenry’s US$40 million funding round
  • GIC, JP Morgan, and HSBC’ Venture Capital Fund on their Series B+ investments in Miotech, an ESG data start up
  • HSBC Investment Bank on its Series B investments in Miotech, Callsign, and Silent Eight

Venture Capital - Company Side

  • WorldRemit on its US$292 million Series E funding round
  • Toqio on its seed funding round led by Seaya and Speedinvest
  • LifeScore on its £11m Series A financing led by Octopus Ventures and Warner Music Group
  • Aztec Network on its Series A funding round led by Paradigm
  • Fertifa Limited, the UK’s first and leading reproductive healthcare benefits provider and provider of a next-generation fertility clinic, on its seed funding round led by Passion Capital

Life Sciences and Healthcare

  • Norgine, a European specialty pharmaceutical company, on the sale of a controlling stake to Goldman Sachs Asset Management
  • Alliance Pharma on its acquisition of US scar treatment brand, ScarAway
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the US$703 million acquisition by CVC of women’s healthcare assets from Teva 
  • TLS Beta on the acquisition of a 30% stake in Stamford Devices, an Ireland-based provider of medical device and drug delivery services and holding company for Aerogen 
  • Actavis UK and Actavis Ireland on its £603 million divestment by Teva to Intas* 
  • Accelovance Inc on its cross-border acquisition of THERAMetrics Holding AG’s CRO subsidiaries in Italy, Germany, and Romania* 
  • Adorial on its acquisition by C4X Discovery Holdings plc*
  • Actavis on its £306 million acquisition of Auden Mckenzie, a pharmaceutical company specialising in the development, licensing and marketing of generic medicines and proprietary brands, making Actavis the largest generics company in the UK
  • Actavis on the divestment of part of its Western European generics sale and marketing business to Aurobindo*

Other

  • CDPQ on its partnership with GIM and joint investment in FNZ, a deal valuing the company at £1.65 billion and being one of the world’s largest fintech transactions of 2018
  • Thomas Cook on the sale of its Belgium airline business to Brussels Airlines, a subsidiary of Lufthansa
  • H&F on the disposal of on the disposal of a minority interest in the Verisure Securitas Direct group to GIC
  • Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
  • Onex on its up to €3.75 billion acquisition of SIG Combibloc Group AG
  • Acano in connection with its US$700 million acquisition by Cisco*
  • Epicor Software Corporation in connection with its acquisition of Dot-Net-IT Limited*

*Matter handled prior to joining Latham

Bar Qualification

  • England and Wales (Solicitor)

Education

  • Legal Practice Course, BPP Law School, London, 2014
  • LL.B. (Hons), King's College London, 2011